Suvizumab
Suvizumab
Suvizumab (pronunciation: soo-vi-zoo-mab) is a monoclonal antibody designed for the treatment of various diseases. It is a type of biopharmaceutical that is developed in a laboratory and designed to bind to specific cells or proteins, which can stimulate the body's immune system to attack those cells.
Etymology
The name "Suvizumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody. The prefix "Suviz-" does not have a specific meaning and is used to ensure the name is unique.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. They are used in cancer treatment.
- Biopharmaceutical: A type of drug produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance is reduced or eliminated.
- Immune System: The body's defense against infectious organisms and other invaders. It is made up of a network of cells, tissues, and organs that work together to protect the body.
- World Health Organization: A specialized agency of the United Nations responsible for international public health.
External links
- Medical encyclopedia article on Suvizumab
- Wikipedia's article - Suvizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski